当前位置: 首页 > 详情页

OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, P.R. China [2]Beijing Key Laboratory of Cancer & Metastasis Research, Capital Medical University, Beijing, P.R. China [3]Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff, U.K. [4]Department of Thoracic Surgery, Beijing Xuanwu Hospital, Capital Medical University, Beijing, P.R. China [5]Department of Thoracic Surgery, Key Laboratory for Carcinogenesis and Translational Research Ministry of Education, Peking University Hospital, Haidian District, Beijing, P.R. China [6]Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, P.R. China
出处:
ISSN:

关键词: Osteopontin lung cancer bone metastasis splicing variant

摘要:
Background: Osteopontin (OPN) is known to be involved in the development of certain cancers, including non-small cell lung cancer (NSCLC). However, its role in tumour progression remains unclear. The present study investigated the expression and biological impact of the OPN variant, OPN-a in NSCLC. Materials and Methods: OPN-a splicing variant expression in human NSCLC tissues was analyzed by real-time qPCR and immunohistochemistry (IHC), respectively. The impact of OPN-a on cellular functions of lung cancer cells was also evaluated. In addition, an in vitro model was developed for the assessment of interactions between lung cancer cells and bone tissue. Results: The expression of OPN-a was higher in lung cancer tissues compared to normal controls. OPN-a promoted the malignant phenotypes of A549 cells by enhancing cell-adherent abilities to bone tissues, which could be mediated by the interaction with the cell surface receptor ava3 integrin. Conclusion: OPN-a may represent a bone metastatic factor in human lung cancer, as well as a potential therapy target.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2015]版:
Q3 ONCOLOGY
最新[2023]版:
Q4 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, P.R. China [2]Beijing Key Laboratory of Cancer & Metastasis Research, Capital Medical University, Beijing, P.R. China
通讯作者:
通讯机构: [*1]Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN Cardiff, U.K. [*2]Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院